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ABSTRACT
Weprovide a summary of the presentationsmade
at the recent Euro-PDT annual Congress.
Presentations covered developments in topical
photodynamic therapy (PDT) pertaining to
dermatological applications. Recognizing the
high prevalence and chronicity of actinic
keratosis, one of the approved indications for
PDT, there were recommendations to pursue field
therapy to treat clinical and preclinical lesions. A
separate section was reserved to review the strong
evidence for the use of daylight PDT for actinic
keratosis and experience of use of this well
tolerated form of PDT was reported from several
countries. Several presentations covered the
remaining approved uses of topical PDT,
Bowen’s disease and basal cell carcinomas, as
well as considering its role in so far unapproved
indications including photorejuvenation.
Funding: Galderma.
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INTRODUCTION
This year the conference was held again in
Barcelona, Spain. Around 250 participants from
Europe, but also Brazil, Canada and Singapore
attended the two-day meeting which this year
mainly focused on the new development and
introduction of daylight-mediated photodynamic
therapy (DL-PDT) in dermatologic therapy.
DAY 1
In his introductory speech, the President of
EURO-PDT, Prof. Lasse Braathen, Berne,
Switzerland, briefly reviewed the journey from
the experimental beginning of PDT to its current
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place as an accepted treatment procedure not
only for the treatment of non-melanoma skin
cancer (NMSC) including lymphomas but also
for other indications like acne, skin
rejuvenation, skin infections and other
inflammatory disorders. Prof. Yolanda
Gilaberte, Huesca, Spain, the Congress
President, reflected on the tradition of the
Annual EURO-PDT Meeting that permits
researchers and clinicians from different
countries get the opportunity not only to learn
but also to interact and exchange knowledge and
experience in the field of PDT (Fig. 1).
Plenary Session I: Epidemiology, Diagnosis
and Consensus
The first plenary session focused on the
epidemiology, diagnosis and consensus
activities in the field of NMSC. Dr. Maria
Fargnoli from L’Aquila presented a large
Italian survey conducted in dermatology
outpatient departments on prevalence and risk
factors of actinic keratoses (AK). The three
highest independent risk factors were age,
previous NMSC, and living in Southern Italy;
protective factors were BMI C 25.0, regular
sunscreen use and lower educational level. Dr.
Maria Teresa Ferna´ndez Figueras from
Barcelona, Spain gave an excellent summary of
her recent research on the ‘‘differentiated
pathway’’ of development of AK to invasive
squamous cell carcinoma (SCC) which
underlines the need of an early treatment even
of thin AK. Prof. Piergiacomo Calzavara-Pinton
from Brescia, Italy reported on the current
project to update existing clinical guidelines of
AK by combination of both new treatment
options like DL-PDT or ingenol mebutate
(IMB) and the preparation of a three-round
Delphi panel. This approach will allow the
development a treatment algorithm which will
be published soon.
Plenary Session II: AK Lesion Versus Field
Therapy Skin Preparation
In the second plenary session, choosing
between lesional and field therapy for AK was
discussed. Prof. Thomas Dirschka from
Wuppertal Germany focused on real life
situations in dermatologic practice and
pointed out that complete lesion clearance is
rarely achieved and, therefore, our treatment
goal should be reduction of number of AK
lesions with a field-directed approach. In the
same series of talks, pretreatment was also
reviewed. Keratolytic therapy in patients with
AK prior to methyl-aminolevulinate PDT
(MAL-PDT) with salicylic acid cream (10%) or
urea cream (40%) was significantly effective in
respect of higher lesion response rates but also
associated with a higher rate of local reactions.
Other preparation methods [curettage,
microdermabrasion with abrasive pads,
microneedling or ablative fractionated laser
systems (AFXL)] presented by Prof. Merete
Hædersdal from Copenhagen, Denmark,
Fig. 1 Prof. Lasse Braathen, Berne Switzerland, President
EURO-PDT and Prof. Yolanda Gilaberte, Huesca, Spain,
Congress President, during the Open Ceremony of the
15th Annual Congress of EURO-PDT
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confirmed these observations. In another study
run by Prof. Gerber from Du¨sseldorf, Germany,
pretreatment of actinic field cancerization with
AFXL or microneedling followed by MAL-PDT
led to increased protoporphyrin IX
concentration and better outcome.
Plenary Session III: Efficacy Data
The third plenary session and main part of the
congress focused on the recent developments of
DL-PDT. Regarding efficacy data, first results on
comparative trials were reported. Dr. Mariateresa
Rossi from Brescia, Italy presented an interesting
study comparing IMB with MAL-PDT on two
symmetrical contralateral areas. Complete
remission rates at 3 months were slightly better
for conventional MAL-PDT, with local skin
reactions more severe and time to healing longer
with IMB. Since there are no direct comparative
trials with diclofenac sodium/hyaluronic acid
(DHA) and DL-PDT, Prof. Calzavara-Pinton and
coworkers presented on an indirect statistical
method (Bucher’s indirect comparison) to
compare these two field-directed approaches. In
the presented study, an adjusted indirect
comparison revealed that mild, moderate or
mild and moderate AK lesions treated with
MAL-DL-PDT were more than four times more
likely to have complete response than lesions
treated with DHA. Christoffer Nielsen from
Copenhagen, Denmark, reported on a sequential
combination study of 5-fluorouracil (5-FU) and
MAL-DL-PDT for AK on the dorsum of the hands.
Overall clearance rate for DL-PDT alone was
already 46%, and increased to 58% in
combination with 5-FU. Since the reporting of
the two COMET-trials in 2014 and 2015
performed in Australia and Europe, which were
the basis for the registration of MAL in
combination with daylight, several trials have
looked for clearance of AK in the long-term and
histologic effects. Dr. Fargnoli presented her trial
with 12-months efficacy data in 34 AK patients
whohave receivedMAL-DL-PDTvs. conventional
PDT (c-PDT) in a single session. The 12-months
recurrence rates did not differ significantly
(DL-PDT 10%, c-PDT 8%) and efficacy outcomes
of the two treatments were similar for scalp AK
lesions and no safety issues were documented
during follow-up. Dr. Beni Grinblat from Sao
Paulo, Brazil reported on his clinical trial where
the histological impact of DL-PDTwas studied on
AK and field cancerized areas close to the visible
lesions. DL-PDT with MAL reduced the
histological parameters of keratinocyte atypia in
AK treated by 82% and improvement of atypia
extensionwasobserved infieldcancerizedareas in
52%.
Plenary Session IV: DL-PDT: How I Do It
Dr. Colin Morton from Stirling, Scotland,
presented on a recently published consensus
paper dealing with the practical approach to the
use of DL-PDT (Fig. 2). DL-PDT is suitable for
patients with AK on face and scalp, lesion severity
should be grade I or II AKs or actinic field damage.
Fig. 2 Audience listening to talk of Dr. Colin Morton,
Stirling, Scotland and Board Member of EURO-PDT on
the recently published European Consensus on practical
approach to the use of daylight-PDT
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Applicationof a SPF[20 sunscreen (non-physical
protectant) is recommended to all sun exposed
areas 15 min before MAL cream is used. Daylight
exposure should commence within 30 min with
an exposure time of 120 min. Relevant outdoor
conditions are not limited, besides temperature
above 10 C and no rain. Afterwards any
remaining MAL cream should be washed off and
the patient should protect their skin for at least
24 h. Prof. Christophe Bedane, Limoges, France
comparedMALDL-PDTwithMALPDTusingblue
light in a small clinical trial with 26 patients with
AK grade I. Regarding response rates there was no
significantdifference after 6 months, butpainwas
significantly lower forDL-PDT (visual analog scale
VAS 2) vs. VAS 7 for blue light. Ana Julia
Garcia-Malinis from Huesca, Spain revealed
another important aspect of DL-PDT. In her
survey, 50 patients receiving MAL DL-PDT
(procedures including curettage and MAL
application prior to daylight exposure) were
monitored. Both mean (6 min) and average
(5 min) time for preparing for DL-PDT in each
individual patient fitted nicely in the routine
clinical practice setting. Prof. Sally Ibbotson from
Dundee, Scotland reported on her 3-yrs
experience with DL-PDT, and pointed out the
extremely well tolerated side effects, especially
pain, with amedian pain score of 1 (range 0–8) in
her patients (n = 60). Since patients have had
experience with various treatments, including
c-PDT, DL-PDT now offers with its favourable
results an efficientway to streamlinePDT services.
In the final talk that evening, Prof. HansChristian
Wulf from Copenhagen, Denmark, the inventor
of the DL-PDT procedure, asked himself the
question if other lamp types like slide or
overhead projectors, white or red LEDs or
natural daylight in a greenhouse can be as
sufficient as DL-PDT. Based on the
protoporphyrin IX (PPIX) weighted fluence rate,
5000 lx seemed to be efficient for complete
activation of PPIX, only white LED needed
12,000 lx. In the greenhouse, data was close to
natural DL, with the advantage that the window
glass prevents sunburn.
The evening continued with finger food,
tapas and wine at the posters. Eight
presentations were given and the three best
were rewarded by a poster prize sponsored by
photonamic, Reinbek, Germany. The third prize
was received by Oscar Munˇoz Moreno-Arrones
from Madrid, Spain who presented 6 patients
with a naevus sebaceous treated with PDT.
Although there was no complete clearance of
the lesions, clinical and cosmetic improvement
was achieved. The second prize was awarded to
Yik Weng Yew from Singapore. His group
treated truncal acne in 15 patients with 5%
aminolevulinic acid for 3 h under occlusion,
followed by illumination with red light (37 J/
cm2) in a single session. 12 weeks later, a 64%
reduction of inflammatory and 24% of
non-inflammatory lesions was still present.
The first prize also went to Spain, Dr.
Garcı´a-Malinis from Huesca used MAL-PDT
for 43 patients with chondrodermatitis
nodularis helicis (Fig. 3). Around 74% of
Fig. 3 Poster viewing session at the 15th Annual Congress
of EURO-PDT in Barcelona, Spain. The Award-winning
poster of Dr. Garcı´a-Malinis on her study of MAL-PDT
for Chondrodermatitis nodularis helicis is on the left
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patients (mean follow up of 20 months)
showed pain relief and resolution of the
inflammatory nodule.
DAY 2
Plenary Session V: AK Prevention
The next morning continued with a focus on
AK prevention. Dr. Claas Ulrich from Berlin,
Germany outlined the importance of raising
awareness of UV-induced cancers especially in
outdoor workers, since within the EC there are
at least 9.1 million workers constantly exposed
to solar radiation. Thus, risk of non-melanoma
skin cancer is obvious and, therefore, screening
and preventive programs within the whole EC
make sense. Dr. Katrine Togsverd-Bo from
Copenhagen, Denmark demonstrated that
prophylactic PDT in organ transplant
recipients under constant immunosuppression
delays onset of AK significantly. After 3 years,
PDT-treated areas developed in 28% AK,
whereas untreated areas showed in 63% AK
(Fig. 4).
Plenary Session VI: BCC
Prof. Uwe Paasch, Leipzig, Germany then took
the opportunity to speak on the collaborative
work together with Prof. Merete Hædersdal
from Copenhagen, Denmark, pretreating
high-risk BCC (n = 32) with ablative
fractionated lasers (AFXL) prior to MAL-PDT.
Clinical cure rates after 3 months were 100% for
AFXL-PDT vs. 88% for c-PDT. However,
histology revealed no difference regarding
tumour clearance after 12 months (63% vs.
56%). Prof. Celeste Brito from Braga, Portugal
then presented her retrospective study on more
than 550 patients with NMSC receiving
MAL-PDT over 10 years. During the average
follow-up period of 5.5 years, lesion-based cure
rates were 99.5%.
Plenary Session VII: Skin Rejuvenation
and Other Indications
Santi Nonell, Professor of Chemistry of the
University of Barcelona then took the
audience to a new interesting therapeutic field
utilizing PDT for antimicrobial purposes. He
presented newly developed photosensitizers,
some in combination with silver nanoparticles
which work well on both gram-positive and
-negative bacteria. Prof. Yolanda Gilaberte then
shared the results of the first multicenter,
randomized controlled clinical trial on
MAL-PDT for onychomycosis. Three sessions
of 40% urea followed by c-PDT with MAL on
diseased nails were performed and evaluated
after 36 weeks. Clinical cure was observed in
almost 20% of patients in the PDT group and
only 6% of controls. No significant side effects
were reported.
In the final session, aesthetic aspects of PDT
were in focus. Prof. Peter Bjerring from Vejle,
Fig. 4 Prof. Luis Torezan, Sao Paulo, Brazil presenting
ﬁrst clinical data on MAL-PDT split-scalp study for AK
enhanced by topical pretreatment with the vitamin D
analogue calcipotriol
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Denmark, Dr. Matteo Tretti Clementoni from
Milan, Italy and again Prof. Arne Gerber
demonstrated that even DL-PDT is a powerful
tool in reversing clinical signs of photoageing.
Combination with fractionated lasers,
microneedling, or sandpaper application are
possible and side effects like post treatment
erythema can be controlled by topical
application of brimonidine tartrate 0.33% gel.
Then Prof. Sigrid Karrer, Regensburg, Germany
presented a randomized study comparing scalp
nerve blocks, intravenous analgesia and cold air
analgesia, and cold air analgesia alone for scalp
and forehead AK treated with MAL-PDT. Scalp
nerve blocks significantly reduced VAS pain
(2.1) but no difference was found in i.v.
analgesia and cold air and cold air alone (VAS
7.3 vs. 8.4). In a small study, Dr. Dario Fai from
Lecce, Italy reported on the use of MAL DL-PDT
in actinic cheilitis. Seven out of eight patients
reached complete response after 2 PDT sessions
7–14 days apart. DL-PDT has also been used in
the treatment of cutaneous leishmaniasis. Prof.
Claes Enk from Jerusalem, Israel demonstrated
an 88.9% cure rate in patients receiving
repetitive DL-PDT once weekly until clinical
and microbiological cure either with daylight
exposure in the hospital garden or at home. The
final presentation was given by Prof. Ann-Marie
Wennberg from Gothenburg, Sweden. She
showed data from a multicentre trial in 153
patients with inflammatory and
non-inflammatory acne lesions. A
concentration of MAL with 80 mg/g was used.
MAL-PDT significantly decreased the number of
inflammatory lesions (43.8% vs. 26.6% in the
vehicle group), and no serious adverse events
were reported.
During the closing ceremony, Prof.
Braathen, Dr. Morton and Prof. Szeimies from
Recklinghausen, Germany awarded the three
winners of the best oral presentations sponsored
by Galderma International, Lausanne,
Switzerland. The third prize received Dr.
Martina Hund from Berlin, Germany for her
presentation on microneedling assisted DL-PDT
for AK. The second prize recognized Beni
Grinblat and his work on histologic
assessment of DL-PDT for AK. And the winner
of the best oral presentation was Christopher
Nissen from Denmark reporting on the
sequential combination of 5-FU and DL-PDT
with MAL. Prof. Braathen then thanked all
speakers for their excellent presentations and
the audience for active participation in the
discussion and reminded all of the European
Clinical Cases Challenge on PDT Competition
were cases including color pictures now can be
submitted (open until December 31st 2016; for
further information, go to http://www.
europdtcontest.org).
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